期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 59, 期 19, 页码 8967-9004出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.6b00908
关键词
-
资金
- Foundation for Applied Medical Research (FIMA)
- University of Navarra (Pamplona, Spain)
- Fundacion Fuentes Dutor
- Ministerio de Economia y Competitividad (FIS) [PI12/00710]
- FSE (Inncorpora-Torres Quevedo grant) [PTQ-12-05641]
- FIS projects [11/02861, 14/01244]
Simultaneous inhibition of phosphodiesterase 5 (PDE5) and histone deacetylases (HDAC) has recently been validated as a potentially novel therapeutic approach for Alzheimers disease (AD). To further extend this concept, we designed and synthesized the first chemical series of dual acting PDE5 and HDAC inhibitors, and we validated this systems therapeutics approach. Following the implementation of structure- and knowledge-based approaches, initial hits were designed and were shown to validate our hypothesis of dual in vitro inhibition. Then, an optimization strategy was pursued to obtain a proper tool compound for in vivo testing in AD models. Initial hits were translated into molecules with adequate cellular functional responses (histone acetylation and cAMP/cGMP response element-binding (CREB) phosphorylation in the nanomolar range), an acceptable therapeutic window (>1 log unit), and the ability to cross the blood-brain barrier, leading to the identification of 7 as a candidate for in vivo proof-of-concept testing.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据